Latest Licensing Agreements News

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.

Avecho Biotechnology reports strong progress in its Phase III clinical trial for a CBD-based insomnia treatment, with recruitment accelerating across multiple Australian sites and interim results expected early next year.

Arovella Therapeutics reported a robust $20.9 million cash position as it prepares for its first-in-human trial of ALA-101 and expands its solid tumour pipeline through new licensing agreements and leadership appointments.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

Streamplay Studio Limited has posted a positive operating cash flow for the first time since its acquisition-led growth strategy began, buoyed by strong game launches and a new multi-year licensing agreement with Amazon.

Hazer Group has forged a strategic alliance with engineering giant KBR to fast-track commercial deployment of its methane pyrolysis technology, supported by a $10.7 million capital raise and promising project developments in Japan.

FirstWave Cloud Technology has secured a $770k contract renewal with Microsoft, marking an 18% uplift and signaling strong growth potential through new AI-powered products and expanded licensing.

Activeport Group Ltd has secured a landmark contract to deploy its advanced network orchestration software across Ishan Technologies’ vast Indian infrastructure, automating connectivity for over 12,000 edge devices and enhancing service delivery for 85,000 customers.